Roflumilast Treatment Shows Promise For Some Patients With COPD, University of Modena And Leiden University Medical Center Study
8/31/2009 8:26:23 AM
Medical News Today -- Roflumilast, an oral, once a day anti-inflammatory agent, improves lung function and reduces exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have chronic respiratory symptoms and are at greater risk of exacerbations. The effect persists even when roflumilast is added to conventional treatment with inhaled long-acting bronchodilators. Thus, roflumilast therapy has the potential to become an important treatment for these patients. These are the conclusions of two Articles published in this week's COPD special edition of The Lancet.